Shire ADHD alliance gives more power to Shionogi's diversifying lineup
This article was originally published in Scrip
Executive Summary
Shionogi is to co-develop and co-commercialise in Japan two drugs for attention-deficit hyperactivity disorder (ADHD) licensed from Shire, in a deal that adds to the Japanese firm's steady move away from its lacklustre anti-infectives business.